title: Platelet reactivity is preferred over genotyping in monitoring efficacy of antiplatelet therapy.
authors.forename: Nicoline J
authors.initials: NJ
authors.lastname: Breet
authors.forename: Jurrien M
authors.initials: JM
authors.lastname: ten Berg
mesh_terms: D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D003324:Coronary Artery Disease / Q000628:therapy*; D054855:Drug-Eluting Stents; D005260:Female; D006801:Humans; D008297:Male; D062645:Percutaneous Coronary Intervention / Q000295:instrumentation*; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011110:Polymorphism, Genetic; D013988:Ticlopidine / Q000031:analogs & derivatives*
chemical_list: D010975:Platelet Aggregation Inhibitors; D001189:Aryl Hydrocarbon Hydroxylases; D013988:Ticlopidine